Deals Of The Week: Value Surprise!
Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen
You may also be interested in...
Takeda’s Tachi Yamada Discusses The Late-Stage Pipeline: An Interview At PSA 2013
In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.
After Inotuzumab: New Platforms Promise More Than Better Antibody-Drug Conjugates
Versatile next-generation antibody-drug conjugate platforms promise to turn out ADCs with better specificity and safety than current technologies, as well as combination therapeutics like bi-specific antibodies, but old-school molecules continue to move through clinical trials and gain approval.
Lemtrada A Game Changer In MS, Genzyme Researchers Say
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.